Meta Pixel

News and Announcements

Carl Zeiss Neurosurgery Purchase Order

  • Published June 21, 2012 12:29PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Optiscan is pleased to announce it has today accepted the first purchase order from Carl Zeiss for its neurosurgery systems.

As foreshadowed in the shareholder update of June 6, these are pre-production prototypes of Optiscan’s rigid endomicroscopy system for neurosurgery to be exclusively supplied to Carl Zeiss, the world’s number one supplier of neurosurgical visualisation equipment. The systems will facilitate the final steps in the regulatory process, and it is expected they will be deployed in clinical trials with key opinion leaders.

The order, valued at approximately $800,000, is expected to be fulfilled in August as assembly of the
prototypes is already largely complete.

This order marks a major milestone in the development of the neurosurgery market for Optiscan’s
technology in partnership with the relevant world leader, Carl Zeiss.

About Optiscan
Optiscan is a global leader in microscopic imaging technologies for medical markets. Optiscan’s
unique and patented technologies enable high-powered microscopes to be miniaturised and used
inside the body. The technology enables microscopic imaging of up to 1000 times magnification to be
achieved. Doctors can use the technology to instantly see cellular level details of tissue without the
requirement to surgically remove tissue (biopsy).

Further information:
Gus Holt, Chairman
Tel (613) 9538 3347
[email protected]

Bruce Andrew, CFO
Tel (613) 9538 3398
[email protected]

To know more about Optiscan Imaging Limited, please click here.

Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets

QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]

Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy

Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]

Join over 45,000+ sophisticated investors

Join Now